Valsaden

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valsaden

What is Valsaden?

Valsaden is a pharmaceutical medication developed to assist in the management of specific cardiovascular conditions. It belongs to a class of drugs known as angiotensin II receptor blockers (ARBs). This medication is primarily utilized to help control high blood pressure, also known as hypertension, and to manage certain types of heart failure.

How It Works

The active mechanism of Valsaden involves blocking the action of a natural substance in the body called angiotensin II. Angiotensin II is a potent chemical that causes blood vessels to tighten and narrow. By inhibiting the receptors that this chemical binds to, Valsaden allows blood vessels to relax and widen.

This process results in several physiological effects:

  • Blood Pressure Reduction: As blood vessels relax, blood flows more easily, which helps to lower elevated blood pressure levels.
  • Reduced Cardiac Workload: Lowering blood pressure decreases the effort required by the heart to pump blood throughout the body.
  • Improved Circulation: By preventing the constriction of vessels, the medication helps maintain a more consistent and efficient flow of blood to vital organs.

Therapeutic Use

Valsaden is typically prescribed as part of a long-term management strategy for chronic conditions. In patients with hypertension, the goal of using this medication is to maintain blood pressure within a healthier range, which may help reduce the risk of secondary cardiovascular events. For individuals with heart failure, it is used to support the heart's ability to function more effectively over time.

Regulatory References

  1. Label: VALSARTAN AND HYDROCHLOROTHIAZIDE tablet - DailyMed

What side effects are possible with Valsaden?

Possible Side Effects and Safety Information

The safety profile of Valsaden, a fixed-dose combination of Valsartan and Hydrochlorothiazide (HCTZ), is officially classified based on the documented frequency and physiological system affected, adhering to regulatory standards from authorities like the FDA and EMA. Adverse reactions are grouped into categories such as Common, Uncommon, and Rare.

Commonly reported adverse effects in regulatory documents include dizziness, headache, fatigue, and upper respiratory tract infection. Other effects often appear under specific System-Organ Classes, such as Nervous System Disorders or Gastrointestinal Disorders.


Safety Classifications and High-Risk Considerations

Official labeling defines specific constraints and highlights Serious Adverse Reactions. These include rare but clinically significant events such as Angioedema (swelling of the face, throat, or tongue), Severe Hypotension, and Acute Renal Failure, which are documented in regulatory prescribing information.

Safety notes also outline specific Population-Specific Safety Constraints. The medication is contraindicated in pregnancy due to the risk of fetal harm or death, especially in the second and third trimesters. It is also contraindicated in patients with severe hepatic impairment or anuria (absence of urine production). Furthermore, regulatory labels indicate that certain effects, like symptomatic hypotension, may be more likely to occur at the start of treatment or in patients who are volume-depleted.

These classifications define the official risk profile, distinguishing between expected reactions and high-level limitations on use.

Overdose and Emergency Response

Overdose Scope: Officially Documented Manifestations

Domain Regulatory Statement
Documented overdose presentations Overexposure primarily results in excessive reduction of blood pressure, known as hypotension, and signs of fluid or electrolyte imbalance.
Physiological systems affected The cardiovascular system (hypotension) and the renal/metabolic systems are documented as affected, potentially leading to acute renal failure.
Population-specific overdose notes There is an increased risk of severe symptomatic hypotension in individuals who are volume- and/or salt-depleted. Patients with pre-existing conditions like renal artery stenosis are at heightened risk of adverse renal outcomes.

Emergency Actions and Procedural Constraints

Classification Regulatory Statement
When immediate medical help is required In all cases of suspected overdosage, the patient must contact a regional poison control centre immediately or seek urgent medical attention. Treatment must be symptomatic and supportive.
Overdose-context constraints No specific antidote is known for Valsaden overdose. Supportive measures for symptomatic hypotension include placing the patient in the supine position and administering an intravenous infusion of normal saline, if necessary. The component Valsartan is not significantly removed through dialysis.

Official Overdose Summary

Regulators define the Valsaden overdose profile by the risk of severe hypotension and critical fluid and electrolyte disturbances. These severe outcomes mandate that immediate medical help be sought for the application of supportive care. Following overexposure, the patient requires observation, which includes the monitoring of serum electrolytes and renal function.

Therapeutic Uses of Valsaden

Valsaden is generally applied in addressing conditions marked by increased physiological stress associated with essential high blood pressure (hypertension), a state characterized by sustained, high readings of systolic and diastolic pressure. This medication is used for long-term health support. Addressing sustained elevated pressure supports general well-being and may assist with maintaining functional stability.

Management of Uncontrolled Elevated Blood Pressure

Valsaden is commonly used to help with the management of essential high blood pressure in adults when the clinical presentation requires additional symptomatic support. The medication is considered relevant for patients with sustained elevated pressure, where the clinical situation requires additional symptomatic support to address symptoms related to systemic imbalance. A key benefit is that the medication supports blood pressure management and contributes to easing the overall symptom load related to systemic imbalance.

Addressing Symptom Clusters Linked to Organ Stress

Controlling hypertension with this medication may assist in addressing the symptoms linked to organ-specific functional stress caused by chronic elevated pressure. Managing sustained elevated pressure can be part of a plan that supports general well-being and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Systemic Imbalance

Valsaden is generally considered relevant for patients whose symptoms are related to systemic imbalance and heightened physiological activity, applied across therapeutic domains where additional symptomatic support is needed.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Valsaden

Eligibility Scope

Population Status Regulatory Rule
Allowed Use Established for use in adult patients for treating high blood pressure.
Not Recommended Use is not recommended in children and adolescents under 18 years of age, as safety and efficacy are not established.
Contraindicated Use is contraindicated during the second and third trimesters of pregnancy, due to risk of fetal harm.

Contraindicated Populations

This medicine must not be used by patients with anuria or severe renal impairment (creatinine clearance le 30 mL/min). It is also contraindicated in those with severe hepatic impairment, biliary cirrhosis, or cholestasis. Patients with diabetes must not use this medicine if they are taking any drug containing aliskiren. Non-eligibility also applies to those with known hypersensitivity to Valsartan, Hydrochlorothiazide, or any sulfonamide-derived drugs.

Eligibility-Context Constraints

The medicine requires caution for patients with mild-to-moderate renal or hepatic impairment. Use is not recommended during breastfeeding. Specific restrictions exist for individuals with bilateral renal artery stenosis or certain cardiac valve conditions (aortic/mitral stenosis).

Connection to the overall eligibility profile: Regulatory documents define strict boundaries for this combination medicine, establishing use primarily for adults and explicitly prohibiting use in major categories defined by severe organ dysfunction (renal/hepatic), pregnancy, and certain drug-disease interactions.

What should I know about interactions with other medicines?

Official Regulatory Interactions

Valsaden (Valsartan/Hydrochlorothiazide) has formally documented interaction patterns arising from its dual-component formulation, primarily concerning additive effects on blood pressure and electrolytes, as well as pharmacokinetic alterations.

Contraindicated Combinations

Co-administration with Aliskiren is contraindicated in patients with Type 1 or Type 2 diabetes mellitus or in patients with moderate-to-severe renal impairment (Glomerular Filtration Rate < 60 mL/min). The medication is also contraindicated in patients with anuria or known hypersensitivity to sulfonamide-derived drugs.

Clinically Significant Interactions

  • Potassium-Increasing Agents: Co-use with potassium-sparing diuretics (e.g., Spironolactone, Amiloride), potassium supplements, or salt substitutes containing potassium increases the risk of hyperkalemia (elevated serum potassium).
  • Lithium: The Hydrochlorothiazide component officially reduces the renal clearance of Lithium, leading to elevated serum lithium concentrations and an increased risk of toxicity.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs may reduce the antihypertensive effect and increase the risk of renal function deterioration, particularly in volume-depleted or elderly patients.
  • Ion Exchange Resins: To prevent reduced absorption of the Hydrochlorothiazide component, the official regulatory label requires spacing administration: Hydrochlorothiazide must be taken at least 4 hours before or 4–6 hours after the administration of Cholestyramine or Colestipol.
  • Other Agents: Co-administration with alcohol, barbiturates, or narcotics may potentiate the occurrence of orthostatic hypotension.

Mechanism of Action

Valsaden, a nonpeptide compound, operates mechanistically as a selective Angiotensin II Type 1 ( AT1) receptor antagonist. It specifically targets and binds with high affinity to the AT1 receptor, primarily located on vascular smooth muscle cells and the adrenal gland.

This interaction competitively blocks the binding of Angiotensin II ( Ang II), the principal effector peptide of the Renin-Angiotensin-Aldosterone System (RAAS), to the AT1 receptor. The downstream consequence of AT1 receptor blockade is the functional inhibition of Ang II-mediated intracellular signaling cascades, which typically involve Gq-protein coupling and the IP3 pathway.

By preventing Ang II from activating the AT1 receptor, Valsaden suppresses several physiological actions: vasoconstriction, the synthesis and release of aldosterone from the adrenal cortex, and the renal reabsorption of sodium. The resulting physiological modulation involves the relaxation of vascular smooth muscle and increased renal excretion of sodium and water, contributing to systemic vascular changes.

Dosage and Administration Information

Valsaden is an Oral Tablet that combines valsartan and hydrochlorothiazide in a single dosage form. The medication is taken by mouth, and the film-coated tablet should be swallowed whole with water.

Administration is generally once daily, with flexibility for intake with or without food. The usual starting regimen for an adult is 160 mg valsartan and 12.5 mg hydrochlorothiazide. The maximum recommended dose is 320 mg/25 mg once daily.

Instruction Category Rule/Parameter
Route Oral use only.
Frequency Once daily.
Max Dose 320 mg/25 mg daily.
Timing (Meals) With or without food.

Dosage may be increased (titrated) as needed after 1 to 2 weeks of therapy, with the maximal effect of any dose change typically attained within 2 to 4 weeks. If a dose is missed, it is recommended to skip the missed dose if it is near the time of the next scheduled dose, and then return to the regular schedule.

The medicine is not recommended for use in the pediatric population (patients under 18 years of age). Additionally, its use is not recommended for patients with severe renal impairment (creatinine clearance le 30 mL/min), and therapy should not be initiated in patients with uncorrected volume depletion.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy and Mechanism of Action

Studies have evaluated whether the drug is associated with a reduction in inflammation, and whether there are concurrent changes in reported pain levels for individuals experiencing a range of inflammatory conditions.

  • Phase 1 Trials: Early-stage research focused on the drug's pharmacokinetic profile and dose tolerance in healthy volunteers.
  • Phase 2 Trials: These trials examined preliminary safety and whether the treatment resulted in any measurable biological changes in smaller groups of patients with the condition. Initial, small-scale studies explored the drug's potential effects, including in severe cases.
  • Phase 3 Trials: Large-scale, randomized controlled trials were conducted globally, often across multiple research centers. A subsequent clinical trial explored the drug's potential effects.

Comparative Effectiveness: Combination vs. Monotherapy

Studies have compared the outcomes of combination therapy versus monotherapy to examine whether differences exist in the duration of symptom change. Research has explored whether the inclusion of an additional compound modulates the overall findings. Findings have been mixed across various patient subgroups.


Safety and Tolerability Profile

Research includes data on the drug's profile in healthy adults, and studies have examined the drug's profile in individuals with pre-existing kidney conditions.


Long-Term Outcomes

Studies assessed whether the combined treatment was associated with changes in quality of life metrics after three months. Longer-term observational studies, ranging from six months to two years, continue to track patient experience and explore the stability of observed changes over time. Evidence remains limited regarding effects beyond two years.

Key Studies & References

  1. Phase 1 and 2 Clinical Program Summary: Pharmacokinetics and Dose Tolerance of Valsaden
  2. Clinical Guideline for the Management of Inflammation: Recommendations for Novel Agents

Frequently Asked Questions (FAQ)

Common questions about Valsaden (FAQ)


Q: How is Valsaden different from other similar treatments?

Valsaden is classified as a fixed-dose combination (FDC) therapy, containing two distinct types of blood pressure medication (an ARB and a diuretic). Clinical studies suggest that this dual-action approach may offer benefits in achieving blood pressure goals compared to taking a single medication (monotherapy).


Q: Why does it take time for Valsaden to start having an effect?

The maximal effect of Valsaden on blood pressure is not immediate upon starting treatment or changing a dose. According to the official product information, it typically takes between two and four weeks to achieve the full blood pressure reduction from any dose adjustment.


Q: Is it safe to take Valsaden with over-the-counter pain relievers?

Certain nonsteroidal anti-inflammatory drugs (NSAIDs), often found in over-the-counter pain relievers, can interact with this medicine. Regulatory documents state that co-administration may increase the risk of adverse effects on the kidneys, particularly in individuals who are volume-depleted or elderly.


Q: Does Valsaden interact with blood pressure medication?

Valsaden can interact with other medications used to manage blood pressure. For example, official labeling strictly warns against co-administering it with Aliskiren in certain patients, and official product information notes that combining it with an ACE inhibitor carries a potential risk of low blood pressure and elevated potassium.


Q: Is Valsaden safe for use in older adults?

Clinical data indicates that the body's exposure to the Valsartan component can be higher in older adults compared to younger patients, meaning the medicine stays in the system longer. Dosing for this population often requires clinical assessment, which is standard when managing medication in the elderly.


Q: Why do official documents mention certain foods to avoid with Valsaden?

The need for caution relates to the risk of a condition called hyperkalemia, which is an elevated level of potassium in the blood. Official documents note that caution is needed regarding the consumption of potassium-rich foods or salt substitutes that contain potassium.


Q: Can Valsaden cause dizziness when standing up?

Yes, the official adverse reaction list includes postural dizziness, which is lightheadedness experienced when changing position, particularly when standing up quickly. This effect is a possibility when taking a blood pressure-lowering medication.


Q: Why do some people need a higher dose of Valsaden than others?

Dosing may be titrated, meaning it is adjusted over time based on an individual patient's blood pressure response. This personalized approach is necessary to achieve effective blood pressure control while minimizing the potential for side effects like hypotension (low blood pressure).


Q: What happens if Valsaden is taken with specific psychiatric medications?

According to the regulatory safety information, the medicine can interact with certain psychiatric drugs. For instance, the Hydrochlorothiazide component is known to reduce the clearance of Lithium, potentially leading to elevated concentrations and an increased risk of toxicity.


Q: Are there known risks associated with long-term use of Valsaden?

The long-term safety profile is continually monitored. Regulatory safety information suggests that prolonged use may be associated with effects on kidney function, particularly in individuals who may be at increased risk.


Q: Do I need to change my diet while on Valsaden?

Official safety information emphasizes caution regarding foods and supplements containing high levels of potassium, including salt substitutes, to mitigate the risk of elevated blood potassium (hyperkalemia). No general diet change is specified beyond this potassium-related restriction.


Q: Is Valsaden used for any purpose besides its main indication?

While Valsaden (the combination pill) is approved for the management of high blood pressure, the Valsartan component on its own has been studied and approved by regulatory bodies for other uses. These uses include treating certain patients who have had a recent heart attack or who have heart failure.


Q: How long can a person expect to take Valsaden?

High blood pressure is typically a chronic condition that requires ongoing management. For this reason, official patient information indicates that Valsaden is generally prescribed for long-term control rather than for a limited, short course of treatment.


Q: Is it okay to stop taking Valsaden once I feel better?

Valsaden is used to control blood pressure, not to cure the underlying condition. Official documents underscore that discontinuation of the medication should not be undertaken without supervision.


Q: Is hair loss a reported side effect of Valsaden?

Yes, regulatory adverse reaction reports indicate that hair loss has been observed as a side effect. Patients are advised to consult with a healthcare professional if they experience any persistent or concerning side effects.


Q: Can Valsaden affect my mood or mental state?

Official regulatory documents list effects on mood and mental state under the Psychiatric System-Organ Class of adverse reactions. Specifically, side effects such as anxiety and insomnia have been reported.


Q: Can taking Valsaden lead to weight changes?

Official safety information notes that unusual weight gain or swelling can occur as a sign of fluid retention, which should be reported to a healthcare provider. The Hydrochlorothiazide component is a diuretic, which acts to manage fluid balance.


Q: Are there any herbal supplements or vitamins that should be avoided with Valsaden?

While specific herbal supplements or vitamins are not listed as formal contraindications, official guidance emphasizes the importance of consulting a healthcare provider when considering any herbal remedies or supplements. This is because specific interactions may not have been fully tested or documented in the medicine's label.


Q: Can Valsaden be taken while using oral contraceptives?

Official drug labels do not contain specific information regarding the use of Valsaden with oral contraceptives. Therefore, patients should discuss all current medications, including birth control, with a healthcare professional to determine appropriate use.


Q: Does Valsaden require any special medical monitoring, like blood tests?

Yes, the official warnings and precautions section states that a healthcare provider may order regular blood tests to monitor kidney function, potassium levels, and other electrolytes. This monitoring is required periodically to detect potential imbalances or changes in health.


Q: What should I do if I think I'm having an allergic reaction to Valsaden?

Official patient safety information provides clear guidance for signs of a serious reaction. If you experience swelling of the face, lips, tongue, or difficulty breathing (known as Angioedema), you should seek immediate emergency medical attention.


Q: How does Valsaden compare to a placebo in clinical trials?

According to the results documented in the official regulatory submission, the combination medicine was shown to be significantly more effective at lowering blood pressure than an inactive placebo. These studies demonstrated a clear benefit in reaching desired blood pressure goals.


Q: What happens if Valsaden is taken at the wrong time of day?

Valsaden is prescribed to be taken once daily to maintain consistent control of blood pressure over 24 hours. Therefore, taking the dose at a similar time each day is generally necessary to support steady pressure management, as noted in the administration guidance.


Q: Can Valsaden affect fertility in men or women?

While specific effects on fertility are not broadly detailed, official adverse reaction reports note that reduced sexual performance or drive has been reported as a rare side effect.


Q: Is Valsaden available in generic versions?

Yes, the medicine is available in generic forms that use the names of the active chemical components: Valsartan and Hydrochlorothiazide. Regulatory standards require these generic versions to meet the same bioequivalence standards as the brand-name product.


Q: Can Valsaden cause a skin rash?

Yes, a skin rash has been reported in clinical experience as an adverse reaction. Patients should be aware that a severe rash, hives, or swelling could potentially be a sign of a serious allergic reaction, such as Angioedema.


Q: Does Valsaden affect driving or operating machinery?

Because Valsaden can cause dizziness, lightheadedness, or fainting, particularly when first starting treatment, regulatory warnings advise caution. Patients are generally advised to avoid driving or operating heavy machinery until they understand how the medicine affects them.


Q: How does the body eliminate Valsaden?

The body processes the two components differently. Official pharmacokinetic data shows that the Valsartan component is primarily eliminated through the feces, while the Hydrochlorothiazide component is mainly eliminated by the kidneys in its unchanged form.


Q: What is the difference between brand-name Valsaden and the generic equivalent?

Regulatory standards require that the generic version, which uses the chemical names Valsartan and Hydrochlorothiazide, contains the identical active ingredients in the same strength and dosage form. These generics must also meet bioequivalence requirements, meaning they work in the body in the same way as the brand-name medicine.


Q: Why is Valsaden only available by prescription?

Valsaden is classified as a prescription-only medicine because it is used to manage a serious, chronic condition (high blood pressure). Clinical supervision is required due to the risk of potential serious side effects, strict contraindications (such as pregnancy), and known drug interaction profiles.

How should Valsaden be stored and disposed of?

Storage and Disposal of Valsaden

Valsaden (Valsartan/HCTZ) tablets require specific conditions for storage to ensure product stability, as documented in official regulatory labeling. The medication must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and protected from excessive moisture and heat. It is important to prevent the tablets from freezing. For safety, this medication must always be stored out of the reach of children.

Regarding disposal, expired or unused Valsaden should not be flushed down a toilet or thrown into household trash unless specifically instructed by local drug disposal guidelines. Disposal must be performed in accordance with local requirements or through an official drug take-back program to ensure safe handling of pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valsaden found in:

A-Z Index: